Co-Authors
This is a "connection" page, showing publications co-authored by SAMIR HANASH and FULIANG CHU.
Connection Strength
0.116
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res. 2023 06 06; 25(1):62.
Score: 0.059
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Res Sq. 2023 Feb 14.
Score: 0.058